Clinical trial
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung…
NCT00321815 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00321815 |
|---|---|
| Title | Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer |
| Official title | A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | PF-3512676 + Erlotinib, Erlotinib |
| Enrollment | 43 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | May 4, 2006 |
| Last update posted | Dec 23, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: